¹⁸F-DOPA PET/computed tomography imaging

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Neuroimaging

Background:

• 18F-DOPA is a radiotracer used in Positron Emission Tomography (PET) imaging.
• It targets the dopaminergic pathway and has applications in oncology and neurology.
• Accurate interpretation requires knowledge of normal biodistribution and potential imaging artifacts.

Purpose of the Study:

• To review the clinical applications of 18F-DOPA PET.
• To highlight the importance of understanding normal 18F-DOPA distribution and variants.
• To discuss potential pitfalls, false-positive, and false-negative findings.

Main Methods:

• Review of existing literature on 18F-DOPA PET imaging.
• Analysis of biodistribution patterns and physiological variants.
• Case examples illustrating clinical utility and interpretation challenges.

Main Results:

• 18F-DOPA PET demonstrates efficacy in assessing dopaminergic pathways, brain tumors, neuroendocrine tumors (NETs), and congenital hyperinsulinism.
• Normal biodistribution and physiological variants are well-characterized.
• Potential for false-positive and false-negative results exists in various clinical scenarios.

Conclusions:

• 18F-DOPA is a valuable radiopharmaceutical with diverse clinical applications.
• Thorough understanding of its behavior is essential for accurate PET scan interpretation.
• Awareness of potential interpretation pitfalls improves diagnostic confidence.